Inhibition of Vascular Smooth Muscle Cell Proliferation and Neointimal Formation in Injured Arteries by a Novel, Oral Mitogen-Activated Protein Kinase/Extracellular Signal–Regulated Kinase Inhibitor
- 23 November 2004
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation
- Vol. 110 (21), 3367-3371
- https://doi.org/10.1161/01.cir.0000147773.86866.cd
Abstract
Background— Mitogen-activated protein kinases (MAPKs) are rapidly induced after arterial injury in different animal models. However, their precise role in vascular smooth muscle cell (VSMC) proliferation and neointimal formation in vivo remains to be determined.This publication has 9 references indexed in Scilit:
- A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 2004
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- Pilot Trial of Oral Rapamycin for Recalcitrant RestenosisCirculation, 2003
- Role of p44/p42 MAP Kinase in the Age-Dependent Increase in Vascular Smooth Muscle Cell Proliferation and Neointimal FormationArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) TrialCirculation, 2002
- Mammalian MAP kinase signalling cascadesNature, 2001
- Atherosclerosis — An Inflammatory DiseaseNew England Journal of Medicine, 1999
- The Regulation of p42/p44 Mitogen-Activated Protein Kinases in the Injured Rat Carotid ArteryJournal of Surgical Research, 1997
- Mitogen-activated protein kinase phosphatase-1 in rat arterial smooth muscle cell proliferation.JCI Insight, 1996